Affymax And Takeda Announce Hematide™ Publication In The New England Journal Of Medicine
Links shared publicly online about this topic.
- 1,624total visits
Affymax And Takeda Announce Hematide™ Publication In The New England Journal Of Medicine
View full resource at medicalnewstoday.com
Tags: Pharma, Phase 2 Clinical Trial, Clinical Trial
Most Recently Shared on November 6, 2009 at 12:54 am By:
#HEALTH Affymax And Takeda Announce Hematideâ„¢ Publication In The New England Journal Of Medicine http://ow.ly/15ZL0Z
Also Shared By:
Affymax and Takeda Announce FDA Approval of Omontys (peginesatide) Injection for the Treatment of Anemia Due to Chronic Kidney Disease (CKD) in Adult Patients on Dialysis
drugs.com — “Omontys (peginesatide) is used to treat anemia due to Chronic Kidney Disease. Includes Omontys side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on March 27, 2012 at 11:41 pm By:
FDA Approves Omontys (peginesatide) for the Treatment of Anemia Due to Chronic Kidney Disease - http://t.co/rluIf9fp
Affymax and Takeda Announce FDA Approval of Omontys (peginesatide) Injection for the Treatment of Anemia Due to Chronic Kidney Disease (CKD) in Adult Patients on Dialysis
drugs.com — “Omontys (peginesatide) is used to treat anemia due to Chronic Kidney Disease. Includes Omontys side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on March 27, 2012 at 11:06 pm By:
Drugs and Devices OW OW Health
Affymax and Takeda Announce FDA Approval of Omontys (peginesatide) Injection for the Treatment of Anemia D... http://t.co/O4BqcAm5 #drug
Affymax and Takeda Announce FDA Approval of OMONTYS® (Peginesatide) Injection for the Treatment of Anemia Due to Chronic Kidney Disease (CKD) in Adult Patients on Dialysis - Yahoo! Finance
finance.yahoo.com — “From Yahoo! Finance: Affymax, Inc. and Takeda Pharmaceutical Company Limited , today announced that the U.S. Food and Drug Administration approved OMONTYS® Injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.” View full resource at finance.yahoo.com
Most Recently Shared on March 27, 2012 at 6:44 pm By:
Luke Timmerman Health Communicator
Affymax conf call coming up fast, 2:45 pm ET/11:45 am PT. http://t.co/8TpSAOyY
Affymax and Takeda to Present Peginesatide Data at the American Society of Nephrology Kidney Week 2011 - Drugs.com MedNews
drugs.com — “Oct 10, 2011 - Affymax, Inc. (Nasdaq AFFY) and Takeda Pharmaceuticals Global Research Development Center, Inc., U.S., today announced data from multiple studies” View full resource at drugs.com
Most Recently Shared on October 10, 2011 at 8:01 pm By:
Drugs and Devices OW OW Health
Affymax and Takeda to Present Peginesatide Data at the American Society of Nephrology Kidney Week 2011: PA... http://t.co/syYwgLDv #drug
Affymax Announces Assignment of March 27, 2012 PDUFA Date for Peginesatide New Drug Application
drugs.com — “Hematide (peginesatide) is a new drug in development for the treatment of anemia in chronic renal failure. Hematide information includes news, clinical trial results and side effects.” View full resource at drugs.com
Most Recently Shared on August 12, 2011 at 3:04 am By:
Drugs and Devices OW OW Health
Affymax Announces Assignment of March 27, 2012 PDUFA Date for Peginesatide New Drug Application: PALO ALTO... http://bit.ly/nM4QV8 #drug
FDA acceptance of peginesatide NDA triggers $10M milestone payment to Affymax
news-medical.net — “Affymax, Inc. today announced that it has received a $10 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize peginesatide (formerly known as Hematide™), Affymax's investigational drug for the treatment of anemia in chronic renal failure patients.” View full resource at news-medical.net
Most Recently Shared on August 10, 2011 at 1:43 pm By:
FDA acceptance of peginesatide NDA triggers $10M milestone payment to Affymax: Affymax, Inc. today announced tha... http://bit.ly/oolpHF
Affymax and Takeda Announce the Submission of a New Drug Application for Peginesatide for the Treatment of Anemia Associated with Chronic Renal Failure in Patients on Dialysis
drugs.com — “Hematide (peginesatide) is a new drug in development for the treatment of anemia in chronic renal failure. Hematide information includes news, clinical trial results and side effects.” View full resource at drugs.com
Most Recently Shared on June 1, 2011 at 1:12 am By:
Drugs and Devices OW OW Health
Affymax and Takeda Announce the Submission of a New Drug Application for Peginesatide for the Treatment of... http://bit.ly/jeqYlY #drug
NDA Submitted for Peginesatide for Anemia - ONA
oncologynurseadvisor.com — “Affymax Inc. and Takeda Pharmaceutical Company Limited announced that they have submitted a NDA to the FDA for peginesatide (formerly known as Hematide) for the treatment of anemia associated with chronic renal failure (CRF) in adult patients on dialysis.” View full resource at oncologynurseadvisor.com
Most Recently Shared on May 31, 2011 at 6:05 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
NDA Submitted for Peginesatide for Anemia http://goo.gl/fb/wPwj7
NDA Submitted for Peginesatide for Anemia - MPR
empr.com — “Affymax Inc. and Takeda Pharmaceutical Company Limited announced that they have submitted a NDA to the FDA for peginesatide (formerly known as Hematide) for the treatment of anemia associated with chronic renal failure (CRF) in adult patients on dialysis.” View full resource at empr.com
Most Recently Shared on May 31, 2011 at 3:18 pm By:
MPR News: NDA Submitted for Peginesatide for Anemia: Affymax Inc. and Takeda Pharmaceutical Company Limited anno... http://bit.ly/kAfRib
Phase 3 Study of Peginesatide for CRF Dialysis Patients with Anemia - MPR
empr.com — “Affymax and Takeda announced additional data from two Phase 3 studies, EMERALD 1 and 2, of peginesatide (formerly known as Hematide) for the treatment of patients with chronic renal failure on dialysis with anemia.” View full resource at empr.com
Most Recently Shared on April 28, 2011 at 3:57 pm By:
MPR News: Phase 3 Study of Peginesatide for CRF Dialysis Patients with Anemia: Affymax and Takeda announced addi... http://bit.ly/krWvDM
Phase 3 Study of Peginesatide for CRF Dialysis Patients with Anemia - ONA
oncologynurseadvisor.com — “Affymax and Takeda announced additional data from two Phase 3 studies, EMERALD 1 and 2, of peginesatide (formerly known as Hematide) for the treatment of patients with chronic renal failure on dialysis with anemia.” View full resource at oncologynurseadvisor.com
Most Recently Shared on April 28, 2011 at 3:02 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Phase 3 Study of Peginesatide for CRF Dialysis Patients with Anemia http://goo.gl/fb/J8t2Q
Affymax And Takeda To Present Additional Peginesatide Phase 3 Data In Dialysis Patients At The NKF 2011 Spring Clinical Meeting
medicalnewstoday.com — “Affymax, Inc. (Nasdaq: AFFY) and Takeda Global Research & Development Center, Inc., U.S., today announced multiple posters on peginesatide (formerly known as Hematide™) have been accepted fo” View full resource at medicalnewstoday.com
Most Recently Shared on March 24, 2011 at 12:05 pm By:
Affymax And Takeda To Present Additional Peginesatide Phase 3 Data In Dialysis Patients At The NKF 2011 Spring Clinica... http://mnt.to/3SGY
Affymax and Takeda Confirm U.S. Registration Strategy for Investigational Drug, Hematide/peginesatide, Following Meeting with FDA
drugs.com — “Hematide (peginesatide) is a new drug in development for the treatment of anemia in chronic renal failure. Hematide information includes news, clinical trial results and side effects.” View full resource at drugs.com
Most Recently Shared on December 1, 2010 at 11:06 pm By:
Drugs and Devices OW OW Health
Affymax and Takeda Confirm U.S. Registration Strategy for Investigational Drug, Hematide/peginesatide, Fol... http://bit.ly/gycSEx #drug
Affymax And Takeda Confirm U.S. Registration Strategy For Investigational Drug, Hematide™/Peginesatide, Following Meeting With FDA
medicalnewstoday.com — “Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Company Limited (TSE, 4502), announced that following pre-New Drug Application (NDA) discussions with the U.S. Food and Drug Administration (” View full resource at medicalnewstoday.com
Most Recently Shared on December 1, 2010 at 9:05 pm By:
Affymax And Takeda Confirm U.S. Registration Strategy For Investigational Drug, Hematide™/Peginesatide, Followin... http://mnt.to/3NnP
Preliminary U.S. Registration Strategy For Investigational Drug, Hematide™ / Peginesatide, To Treat Anemia In Chronic Renal Failure
medicalnewstoday.com — “Affymax, Inc. and Takeda Pharmaceutical Company Limited announced that the companies have decided on a preliminary strategic path forward for the investigational drug, Hematide™/peginesatid” View full resource at medicalnewstoday.com
Most Recently Shared on August 6, 2010 at 6:37 pm By:
Preliminary U.S. Registration Strategy For Investigational Drug, Hematideâ„¢ / Peginesatide, To Treat Anemia In Chronic R.. http://dld.bz/qQgr
Advertisement
MNT Clinical Trials
@mnt_clinical
Affymax And Takeda Announce Hematide™ Publication In The New England Journal Of Medicine: Affymax, Inc. .. http://bit.ly/4zpS8Q
1 year ago...